Protection against leptospirosis conferred by Mycobacterium bovis BCG expressing antigens from Leptospira interrogans
- PMID: 33176938
- DOI: 10.1016/j.vaccine.2020.10.086
Protection against leptospirosis conferred by Mycobacterium bovis BCG expressing antigens from Leptospira interrogans
Abstract
Leptospirosis is a zoonotic disease worldwide and caused by the pathogenic spirochetes of the genus Leptospira. Bacterins make up the vaccines used against leptospirosis, but they only succeed in providing short-term and serovar-specific protection. The use of Mycobacterium bovis BCG as a live vaccine vector expressing leptospiral antigens is a promising alternative, particularly due to its adjuvant properties. Four distinct portions P1 (lipL32), P2 (ligAni), P3 (lemA:ligAni) and P4 (lipL32:lemA) of a recombinant chimera composed of the lipL32, lemA and ligANI genes from Leptospira interrogans were cloned individually according to the BioBricks® strategy in the plasmid pUP500/PpAN. These constructs were individually transformed into a BCG Pasteur strain, and protein expression was detected by Western blot. For vaccination, 5 groups of 10 Golden Syrian hamsters were used, aged 4-6 weeks - group 1, rBCG (LipL32); group 2, rBCG (LigAni); group 3, rBCG (LemA:LigAni); group 4, (LipL32:LemA); group 5, wild-type BCG Pasteur (negative control). Two doses containing 106 CFU of rBCG were administered subcutaneously, the challenge was performed with 5 × LD50 of Leptospira interrogans serovar Copenhageni L1-130, and the animals were observed for a 30-day period until the endpoint was reached. Humoral immunity was assessed via indirect ELISA, while renal colonisation was assessed by culture and quantitative real-time PCR. All vaccinated groups were protected against lethal challenge and renal colonisation, in comparison with negative control group (P < 0.05). Recombinant vaccines were not effective at inducing significant humoral immunity, which suggests the induction of cellular immunity - a characteristic of M. bovis BCG. In conclusion, all formulations provide 100% significant protection against leptospirosis in hamsters with no renal colonisation. The use of rBCG as a vaccine vector represents a promising alternative for the control of animal leptospirosis, allowing for protection against clinical signs of leptospirosis and renal colonisation.
Keywords: BioBricks; Chimera; LemA; LigAni; LipL32; Vectored vaccine.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Revisiting the Development of Vaccines Against Pathogenic Leptospira: Innovative Approaches, Present Challenges, and Future Perspectives.Front Immunol. 2022 Jan 3;12:760291. doi: 10.3389/fimmu.2021.760291. eCollection 2021. Front Immunol. 2022. PMID: 35046936 Free PMC article. Review.
-
TonB-dependent receptor epitopes expressed in M. bovis BCG induced significant protection in the hamster model of leptospirosis.Appl Microbiol Biotechnol. 2022 Jan;106(1):173-184. doi: 10.1007/s00253-021-11726-9. Epub 2021 Dec 11. Appl Microbiol Biotechnol. 2022. PMID: 34893930 Free PMC article.
-
Recombinant BCG strains expressing chimeric proteins derived from Leptospira protect hamsters against leptospirosis.Vaccine. 2019 Feb 4;37(6):776-782. doi: 10.1016/j.vaccine.2018.12.050. Epub 2019 Jan 7. Vaccine. 2019. PMID: 30630695
-
Characterization of cellular immune response in hamsters immunized with recombinant vaccines against leptospirosis based on LipL32:LemA:LigAni chimeric protein.Microb Pathog. 2023 Nov;184:106378. doi: 10.1016/j.micpath.2023.106378. Epub 2023 Oct 4. Microb Pathog. 2023. PMID: 37802158
-
Sigma factors of RNA polymerase in the pathogenic spirochaete Leptospira interrogans, the causative agent of leptospirosis.FASEB J. 2023 Oct;37(10):e23163. doi: 10.1096/fj.202300252RRR. FASEB J. 2023. PMID: 37688587 Review.
Cited by
-
Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy.Pathogens. 2023 May 31;12(6):787. doi: 10.3390/pathogens12060787. Pathogens. 2023. PMID: 37375478 Free PMC article. Review.
-
A New Recombinant Multiepitope Chimeric Protein of Leptospira interrogans Is a Promising Marker for the Serodiagnosis of Leptospirosis.Trop Med Infect Dis. 2022 Nov 9;7(11):362. doi: 10.3390/tropicalmed7110362. Trop Med Infect Dis. 2022. PMID: 36355904 Free PMC article.
-
Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis.Vaccines (Basel). 2022 Jan 14;10(1):123. doi: 10.3390/vaccines10010123. Vaccines (Basel). 2022. PMID: 35062784 Free PMC article. Review.
-
Revisiting the Development of Vaccines Against Pathogenic Leptospira: Innovative Approaches, Present Challenges, and Future Perspectives.Front Immunol. 2022 Jan 3;12:760291. doi: 10.3389/fimmu.2021.760291. eCollection 2021. Front Immunol. 2022. PMID: 35046936 Free PMC article. Review.
-
TonB-dependent receptor epitopes expressed in M. bovis BCG induced significant protection in the hamster model of leptospirosis.Appl Microbiol Biotechnol. 2022 Jan;106(1):173-184. doi: 10.1007/s00253-021-11726-9. Epub 2021 Dec 11. Appl Microbiol Biotechnol. 2022. PMID: 34893930 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
